Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,001–3,100 of 4,628
Diagnosis of pleuroparenchymal fibroelastosis: A review
Tetikkurt, C., Öztürk, B. Ç., & Güngördü, N. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2363 · Cited by 4
Marin, M. P., & Salvatore, M. M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-022-03789-7 · Cited by 5
Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!
Gozal, D., & Kolb, M. R. J. (2023) · European Respiratory Journal · doi:10.1183/13993003.01797-2022 · Cited by 4
Self-citationNolan, C. M., Schofield, S. J., Maddocks, M. M., Patel, S., Barker, R. E., Walsh, J. A., Polgar, O., George, P. M., Molyneaux, P. L., Maher, T. M., et al. (2023) · Respirology · doi:10.1111/resp.14494 · Cited by 4
Contemporary Concise Review 2022: Interstitial lung disease
Smith, D. J. F., & Jenkins, G. R. (2023) · Respirology · doi:10.1111/resp.14511 · Cited by 6
Microscopic polyangiitis initially presenting with idiopathic pulmonary fibrosis: a case report
Shao, C., Chen, R., Huang, H. F., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1157922 · Cited by 4
“After a global multidisciplinary discussion (MDD), he was diagnosed with idiopathic pulmonary fibrosis (IPF) and enrolled in the INPULSIS clinical trial (3).”
BackgroundInterstitial lung disease: a decade of progress and hope
Adegunsoye, A. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00157-1 · Cited by 4
Castelli, G., Cocconcelli, E., Bernardinello, N., Balestro, E., & Spagnolo, P. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00315-y · Cited by 4
Zou, Y., Hou, X., Anegondi, N., Negahdar, M., Cheung, D. S., Belloni, P., de Crespigny, A. J., & Coimbra, A. F. (2023) · ERJ Open Research · doi:10.1183/23120541.00210-2023 · Cited by 4
Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis—Reply
Maher, T. M., Ford, P., & Wijsenbeek, M. S. (2023) · JAMA · doi:10.1001/jama.2023.12640 · Cited by 4
Planas‐Cerezales, L., Fabbri, L., & Pearmain, L. (2023) · Breathe · doi:10.1183/20734735.0090-2023 · Cited by 4
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis
Simonetti, J., Sgalla, G., & Richeldi, L. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2268014 · Cited by 4
Self-citationGuerra, X., Rennotte, S., Fetita, C. I., Boubaya, M., Debray, M., Israël‐Biet, D., Bernaudin, J., Valeyre, D., Cadranel, J. L., Naccache, J., et al. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101058 · Cited by 4
Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice
Miao, Y., Yang, Y., Li, X., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20914 · Cited by 4
Jiao, T., Wang, Y., Lin, X., Song, W., Wang, L., Tapu, S. R., Xu, L., Nie, L., Zhang, Q., & Li, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1256156 · Cited by 6
“Another drug, nintedanib, is approved for the treatment of lung fibrosis in patients with IPF (28–30).”
BackgroundImaduddin, U., Berbudi, A., & Rohmawaty, E. (2024) · Journal of Experimental Pharmacology · doi:10.2147/jep.s439932 · Cited by 6
Yamamura, K., Hara, J., Watanabe, S., Kobayashi, T., Kase, K., Takeda, Y., Terada, N., Koba, H., Tambo, Y., Ohkura, N., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1443 · Cited by 6
AJRCCM : 100-Y ear A nniversary . Progress in Interstitial Lung Disease
Kaner, R. J., Brown, K. K., & Martínez, F. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201703-0584ed · Cited by 4
Self-citationMolecular Diagnosis and Targeting for Lung Cancer
Yoneda, K., & Tanaka, F. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-6469-2_1 · Cited by 6
Burgess, J. K., Muizer, K., Brandsma, C., & Heijink, I. H. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_9 · Cited by 4
Pannu, J. K., Hewlett, J. C., Smith, A. B., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.44 · Cited by 4
Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Авдеев, С. Н., & Трушенко, Н. В. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-15-131-136 · Cited by 5
LaCamera, P. P., Limb, S. L., Haselkorn, T., Morgenthien, E. A., Stauffer, J. L., & Wencel, M. L. (2019) · Chronic Respiratory Disease · doi:10.1177/1479973119879678 · Cited by 4
Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
Imai, R., & Tomishima, Y. (2020) · Respirology Case Reports · doi:10.1002/rcr2.533 · Cited by 3
“The patient continues to receive follow-up in the outpatient clinic to monitor LV function and his IPF and he has not experienced heart failure since his discharge.”
BackgroundInfluentialRethinking respiratory function laboratories in the era of coronavirus disease 2019
Lombardi, C. M., Milanese, M., & Cottini, M. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.05.021 · Cited by 4
Wapenaar, M., Bendstrup, E. M., Molina‐Molina, M., Stessel, M. K. N., Huremovic, J., Bakker, E. W. P., Kardys, I., Aerts, J. G. J. V., & Wijsenbeek, M. S. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.9433 · Cited by 8
Abe, M., Tsushima, K., Yoshioka, K., Sakayori, M., Suzuki, K., Hirasawa, Y., Kawasaki, T., Ikari, J., Terada, J., & Tatsumi, K. (2020) · Advances in respiratory medicine · doi:10.5603/arm.a2020.0137 · Cited by 5
Li, L., Zhu, H., Wang, H., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0737-1 · Cited by 4
Nishiyama, O., Kataoka, K., Ando, M., Arizono, S., Morino, A., Nishimura, K., Ogawa, T., Shiraki, A., Watanabe, F., Kozu, R., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00321-2021 · Cited by 5
Arai, T., Matsuoka, H., Hirose, M., Kida, H., Yamamoto, S., Ogata, Y., Mori, M., Hatsuda, K., Sugimoto, C., Tachibana, K., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-000889 · Cited by 5
Self-citationThe phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages
Matsuhira, T., Nishiyama, O., Tabata, Y., Kurashimo, S., Sano, H., Iwanaga, T., & Tohda, Y. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101118 · Cited by 7
Patient-Centredness and Patient-Reported Measures (PRMs) in Palliation of Lung Disease
Russell, A., & Saketkoo, L. A. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_4 · Cited by 6
Methotrexate and The Lung in Rheumatoid Arthritis
Nokhatha, S. A. A., Harrington, R., & Conway, R. P. (2020) · EMJ Rheumatology · doi:10.33590/emjrheumatol/20-00074 · Cited by 3
What is new in the treatment of interstitial lung diseases
Sotiropoulou, V., Karampitsakos, T., Katsaras, M., Παπαϊωάννου, Ο., Tsiri, P., Sampsonas, F., & Tzouvelekis, A. (2023) · Pneumon · doi:10.18332/pne/161867 · Cited by 4
Promising new treatment targets in patients with fibrosing lung disorders
Šterclová, M., & Vasakova, M. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i11.668 · Cited by 4
Hypertension pulmonaire au cours des maladies respiratoires chroniques
Cottin, V. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.07.006 · Cited by 5
Self-citationRisk Factors and Biomarkers of RA-ILD
Doyle, T. J., Dellaripa, P. F., & Rosas, I. O. (2017) · Respiratory medicine · doi:10.1007/978-3-319-68888-6_5 · Cited by 4
The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer?
Rangarajan, S., & Lee, J. S. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0222ed · Cited by 4
Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
Prasse, A., Bonella, F., Müller‐Ladner, U., Witte, T., Hunzelmann, N., & Distler, J. H. W. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-00724-y · Cited by 4
“Angesichts des hohen Risikos von behandlungsbedingten NebenwirkungenundMortalität ist eine sorgfältige Auswahl der Patienten für diese Art der Behandlung von entscheidender Bedeutung [29].”
BackgroundInfluentialA novel approach to the treatment of fibrosing interstitial lung diseases
Brovko, M., Анатольевна, А. Л., Sholomova, V. I., Novikov, P. I., Yanakaeva, A., & Moiseev, S. V. (2020) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2020-1-61-66 · Cited by 4
Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis
Ochi, Y., Kato, M., Fujioka, M., et al. (2020) · Respirology Case Reports · doi:10.1002/rcr2.628 · Cited by 4
“It is used to treat idiopathic pulmonary fibrosis (IPF) [1,2].”
BackgroundInfluentialDiverse Pathological Findings of Interstitial Lung Disease in a Patient with Dyskeratosis Congenita
Otoshi, R., Baba, T., Shintani, R., Kitamura, H., Yamaguchi, Y., Hamanoue, H., Mizuguchi, T., Matsumoto, N., Okudela, K., Takemura, T., et al. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5143-20 · Cited by 4
SEVERE HEPATOTOXICITY SECONDARY TO NINTEDANIB
Jiménez, M. L., Carrasco, C. H., & Cano, M. D. C. F. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7585/2020 · Cited by 4
FROM IDIOPATHIC FIBROSING ALVEOLITIS TO IDIOPATIC LUNGS FIBROSIS
Вячеславович, А. А., & Lesnyak, V. N. (2016) · Journal of clinical practice · doi:10.17816/clinpract7458-65 · Cited by 5
Guleria, R., Chaudhry, D., Singh, V., Kumar, R., Nangia, V., Dhar, R., Agarwal, R., Jindal, A., Madan, K., Behera, D., et al. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-60-2-91 · Cited by 7
(2000) · Time to knit · doi:10.1016/j.ypdi.2015.02.057 · Cited by 4
Diagnostic Delay in Idiopathic Pulmonary Fibrosis: Where the Rubber Meets the Road
Adegunsoye, A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201812-883ed · Cited by 4
Toward Realizing the Full Potential of Registries in Interstitial Lung Disease
Durheim, M. T. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-1077ed · Cited by 4
Wong, A. M., Lu, J., Dorfman, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-610010/v1 · Cited by 4
Lang, N. J., Gote-Schniering, J., Porras-Gonzalez, D., Yang, L., Sadeleer, L. D., Jentzsch, R. C., Shitov, V. A., Zhou, S., Ansari, M., Agami, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.16.524219 · Cited by 4
Zheng, J., Wu, J., Xie, L., Huang, Y., Hong, J., & Chen, C. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001695 · Cited by 4
Yang, J., Lu, D., Sun, Y., Qiu, M., Zhao, T., Yan, B., Wang, S., Shao, Z., Wang, D., Li, T., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00524 · Cited by 3
Majewski, S., Górska, K., Lewandowska, K. B., Martusewicz-Boros, M. M., Sobiecka, M., & Piotrowski, W. J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1586197 · Cited by 8
Qin, S., Zhu, Y., Liu, Y., Xie, H., Zhang, J., Zhang, C., & Xu, G. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152169 · Cited by 3
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Swisher, J. W., & Weaver, E. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335815 · Cited by 3
Zhang, Y., Cen, Z., Ding, Q., Ying, Y., Lv, C., & Wu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-08969-1 · Cited by 5
Resolution of innate immune cells with proresolving lipid mediators in idiopathic pulmonary fibrosis
Ang, Y., Ng, A. J. K., Liao, W., Wong, K. Y. K., Wong, W. S. F., & Peh, H. Y. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf100 · Cited by 3
Yu, W.-K., Yang, Y.-P., Shen, H., Shen, H.-C., Chiou, S.-H., Ko, Y., Su, V. Y., Su, V. Y.-F., & Yang, K. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.005 · Cited by 3
Bertuccio, F. R., Baio, N., Perrotta, F., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092310 · Cited by 3
“Initially developed as an antiangiogenic agent in oncology, nintedanib was subsequently approved for the treatment of IPF and, more recently, for progressive pulmonary fibrosis (PPF) of non-IPF origin based on the positive outcomes of the INBUILD trial [22,23].”
Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
Maher, T. M., Jenkins, G. R., Bonella, F., Assassi, S., Diefenbach, C., Ittrich, C., Rohr, K. B., & Kolb, M. (2025) · ERJ Open Research · doi:10.1183/23120541.00158-2025 · Cited by 6
Self-citationSeeliger, B., Ruwisch, J., Sand, J. M. B., Simões, F. B., Jessen, H., Boerner, E. B., Fuge, J., Sewald, K., Welte, T., Wendel‐Garcia, P. D., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.08.047 · Cited by 4
Hu, Y., Zeng, S., Tang, J., Liu, Z., & Shang, H. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109064 · Cited by 3
Inhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities
Gao, X., Li, X., Zhang, C., Zhou, J., Gu, K., Liu, X., & Bai, C. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157048 · Cited by 4
Han, Z., Cao, S., Tai, Y., Li, W., Sang, Y. P., Li, G., Zuo, H. X., Xing, Y., Li, M. Y., Ma, J., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115725 · Cited by 4
Economic burden and cost drivers of interstitial lung disease: a systematic review
Chiew, S. Y., Mohammed, M., & Ong, S. C. (2025) · The European Journal of Health Economics · doi:10.1007/s10198-025-01836-w · Cited by 4
“The reduction was likely due to improvements in outpatient ILD management, such as the initiation of antifibrotic therapy, which reduces the risk of acute exacerbation and hospitali - sation [ 59 , 60 ].”
Orfanos, S., Deeney, B. T., Cao, G., Karmacharya, N., Ravi, A., Koziol‐White, C. J., Yang, Q., Ostrom, R. S., & Panettieri, R. A. (2025) · Respiratory Research · doi:10.1186/s12931-025-03387-3 · Cited by 7
Zhao, C., Xiao, A., Chen, C., Mu, W., Li, W.-Y., & Chang, L. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102889 · Cited by 4
Muscato, G., Libra, A., Reina, C., Gili, E., Fruciano, M., Martella, S., Palmucci, S., Spicuzza, L., Sambataro, G., & Vancheri, C. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04120-6 · Cited by 3
Emerging Therapies in Pulmonary Fibrosis
Etchingham-Coll, H., Temizel, E., Okezie-Enyioma, N., Martin, N., Kaenmuang, P., Coghlan, S., Spagnolo, P., & Chaudhuri, N. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00349-y · Cited by 6
Wang, Y., Liu, X., Xuan, W., Huang, W., Zhu, Y., Mao, C., & Liu, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.003 · Cited by 7
Shahzad, H., Afzaal, U., Saleem, F., Gul, A. H., Thummar, F. R., Murtaza, H. N., Gelan, A. A., Ahsan, M., Irfan, R., Nawaz, A., et al. (2026) · The Clinical Respiratory Journal · doi:10.1111/crj.70181 · Cited by 7
Old and emerging therapies for childhood interstitial lung disease (chILD): a systematic review
Tonazzo, V., Castaldo, R. J., Zanconato, S., Carraro, S., & Ferraro, V. A. (2026) · European Respiratory Review · doi:10.1183/16000617.0062-2025 · Cited by 4
Juan-Guardela, B. M., & Herazo-Maya, J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag121 · Cited by 3
Chen, Y., Hu, L., Fu, Q., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121597 · Cited by 3
Idiopathic interstitial pneumonias in 2015: A new era
Corte, T. J., Collard, H. R., & Wells, A. U. (2015) · Respirology · doi:10.1111/resp.12559 · Cited by 3
Self-citationChambers, D. C. (2015) · Respirology · doi:10.1111/resp.12580 · Cited by 3
Awasthi, N., Schwarz, M. A., Kaurich, Q., Zhang, C., Hilberg, F., & Schwarz, R. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145999 · Cited by 5
“Nintedanib is an approved treatment for non-small cell lung cancer (NSCLC) as well as idiopathic pulmonary fibrosis (30, 31).”
BackgroundHistorical eye on IPF: a cohort study redefining the mortality scenario
Tomassetti, S., Ravaglia, C., Piciucchi, S., Ryu, J. H., Wells, A. U., Donati, L., Dubini, A., Klersy, C., Luzzi, V., Gori, L., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1151922 · Cited by 4
Lv, W., Mao, H., Ruan, Y., Li, S., Shimizu, K., Zhang, L., & Zhang, C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122071 · Cited by 4
Rajagopal, S., Rajadurai, M., Aavula, T., Aji, A., & Sakthivel, V. (2022) · Asian Journal of Biological Sciences · doi:10.3923/ajbs.2022.271.279 · Cited by 3
Shimizu, T., Sagara, A., Fukuchi, Y., & Muto, A. (2024) · Oncology Letters · doi:10.3892/ol.2024.14254 · Cited by 3
Juliá-Serdà, G., Navarro-Esteva, J., Doreste-Salgado, L., et al. (2024) · Cureus · doi:10.7759/cureus.57307 · Cited by 3
“Previous studies have also shown the beneficial effect of these drugs in slowing lung function decline, which justifies their use in our healthcare system since 2014 [24,25].”
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases
Jiang, S., Desmarais, J., Chu, C., & Zhu, J. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101945 · Cited by 3
Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
Perrotta, F., Zamparelli, S. S., D’Agnano, V., Montella, A., Fomez, R., Pagliaro, R., Schiattarella, A., Cazzola, M., Bianco, A., & Mariniello, D. F. (2024) · Biomedicines · doi:10.3390/biomedicines12071384 · Cited by 4
Competing Causes of Death in Idiopathic Pulmonary Fibrosis
Thenappan, A., Maher, T. M., Yazbeck, L., Jenkins, G. R., Johnson, S. R., Stewart, I. D., Oldham, J. M., & Molyneaux, P. L. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0595rl · Cited by 4
Villar, A., Rodríguez‐Nieto, M. J., Cano-Jiménez, E., Ortiz, A. R., Morros, M., Ramon, A., & Armengol, S. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03186-4 · Cited by 3
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis
Agema, B. C., Berrich, M., Seuren, L., Sassen, S. D. T., Miedema, J. R., Koch, B. C. P., Wijsenbeek, M. S., Koolen, S. L. W., Mathijssen, R. H. J., & Veerman, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117341 · Cited by 3
Huang, Y., Zhao, L., Zhao, Y., Fan, Y., Gao, L., Lu, H., Wang, X., Mo, D., & Wang, D. (2024) · International Dental Journal · doi:10.1016/j.identj.2024.09.024 · Cited by 3
Lamellarin D Acts as an Inhibitor of Type I Collagen Production
Okuno, D., Sakamoto, N., Hayashi, H., et al. (2025) · ChemMedChem · doi:10.1002/cmdc.202401001 · Cited by 3
Beyond the Graft: Recurrence of Interstitial Lung Diseases Post Transplant
Ntiamoah, P., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041093 · Cited by 4
Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis
Mullholand, J. B., GROSSMAN, C. E., & Perelas, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041317 · Cited by 4
“Despite the progress made in understanding its pathogenesis, the therapies available to date have only been shown to reduce the rate of disease progression without a major effect on symptom burden or quality of life [2,3].”
Air trapping in patients with idiopathic pulmonary fibrosis: a retrospective case—control study
Kim, T. H., Kim, M. A., Youn, S. H., Kwon, Y. S., Kim, H. J., Park, J. S., & Park, S. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-91060-6 · Cited by 3
Li, Q., Zhou, X., Yang, Y., Zhang, Q., Li, Z., Han, H., Yuan, F., Deng, H., Lei, H., & Duan, Y. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102817 · Cited by 5
Targeted therapy for idiopathic pulmonary fibrosis: a bibliometric analysis of 2004–2024
Zhang, X., Yuan, Z., Shi, X., & Yang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1543571 · Cited by 3
Criner, R. N., Naranjo, M., D’Alonzo, G. E., & Weaver, S. (2025) · Biomedicines · doi:10.3390/biomedicines13040808 · Cited by 4
“Similar to ASCEND, the study found nintedanib had a similar slowing of FVC decline compared to placebo with notable adverse events of diarrhea [23].”
Yu, S., Liu, K., Zhou, F., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119965 · Cited by 3
Progress through Persistence — Turning the Page in Pulmonary Fibrosis Clinical Trials
Lee, J. S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505760 · Cited by 4
Sand, J. M. B., Frederiksen, P., John, A. E., Simões, F. B., Hoyer, N., Prior, T. S., Avdic-Belltheus, A., Molyneaux, P. L., Stewart, I. D., Fainberg, H. P., et al. (2025) · Thorax · doi:10.1136/thorax-2024-221868 · Cited by 4
Use of Spirometry in Pulmonary Function Evaluation
Mohning, M. P., & Krefft, S. D. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.04.001 · Cited by 4
Moua, T., & Benzo, R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2539540 · Cited by 4
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.